RxDoctor Payments Data

Thomas Brooks, MD

Interventional Pain Medicine · Elkhorn, NENPI 1346293651

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Nevro Corp. at 47.3% of the total. Reporting peaked in 2019 at $3,719 and has fallen 79.5% since, to $762 in 2025.

$13,286in general payments, 2019–2025

Across 176 payments — averaging $75.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$6K
  • Medtronic$2K
  • SPR Therapeutics, Inc$1K
  • Relievant Medsystems, Inc.$1K
  • Si-bone, Inc.$792
  • Boston Scientific$412
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$8506%
  • Speaking & faculty fees$2,97522%
  • Travel & lodging$1,62412%
  • Food & beverage$7,83759%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$202,443
Medicare patients
326
Services billed
6,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine29$5,020
Fentanyl15$1,815
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$874
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$598
Gabapentin18$191
Tramadol Hcl15$187
Methylprednisolone24$170
Oxycodone Hcl15$125

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Elkhorn

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →